Trial Profile
Explorative Open Phase II-study, Food Allergy Suppression Therapy During Protection With Xolair
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Acronyms FASTX
- 01 Apr 2021 Results for explorative analysis of this pilot study help to improve understanding on the immunological effects of OT used to facilitate OIT, published in the Scandinavian Journal of Immunology
- 23 Aug 2018 Planned End Date changed from 1 Oct 2017 to 1 Oct 2020.
- 23 Aug 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2020.